ADRX ADRX
Company Profile ↓Company Overview
ADRX (ADRX) is a publicly traded company listed on with a market capitalization of $2.05B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 36.1%, reflecting efficient use of shareholder capital.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -57.7%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -57.65% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +3.82% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.1%.
- Generates positive free cash flow.
CONS
- Earnings shrank at -57.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 0 | 208.00K | 2.14M | 746.00K |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 17.89M | 21.33M | 29.20M | 30.64M |
| Operating Income | -17.89M | -21.12M | -27.06M | -29.89M |
| EBITDA | -17.37M | -20.50M | -26.34M | -29.16M |
| Interest Expense | - | - | - | - |
| Pretax Income | -15.55M | -18.09M | -22.67M | -25.76M |
| Tax Provision | - | - | - | - |
| Net Income | -15.55M | -18.09M | -22.67M | -25.76M |
| Diluted EPS | -0.21 | - | -0.22 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 3.45M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 58.23M | 91.81M |
| Operating Income | -58.23M | -88.36M |
| EBITDA | -56.73M | -86.04M |
| Interest Expense | - | - |
| Pretax Income | -46.36M | -73.09M |
| Tax Provision | - | - |
| Net Income | -46.36M | -73.09M |
| Diluted EPS | -0.62 | -0.97 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 233.45M | 507.65M |
| Current Assets | 225.67M | 493.38M |
| Cash & Equivalents | 14.03M | 66.52M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 370.60M | 709.91M |
| Current Liabilities | 8.94M | 30.48M |
| Long Term Debt | - | - |
| Total Debt | 4.33M | 7.74M |
| Total Equity | -137.15M | -202.25M |
| Shares Outstanding | 102.20M | 102.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -48.56M | 262.29M |
| Investing Cash Flow | 39.51M | -209.93M |
| Financing Cash Flow | 225.00K | 97.00K |
| Capital Expenditure | -455.00K | -2.94M |
| Free Cash Flow | -49.02M | 259.35M |
| Net Change in Cash | -8.82M | 52.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | -2,562.0% |
| Net Margin % | - | -2,119.1% |
| ROE % | 33.8% | 36.1% |
| ROCE % | -25.9% | -18.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADRX
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
ADARx Pharmaceuticals (ADRX) has just completed a US$446.25 million IPO at US$17 per share, placing the RNA-focused biotech at roughly US$2.1 billion in market value. The first sessions post listing have been active for ADARx Pharmaceutical…
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering…
ADRX — Frequently Asked Questions
What is the current share price of ADRX?
As of 2026-09-28 16:31 PDT, ADRX trades at $20.09 on NASDAQ/NYSE. Its 52-week range is $19.35 to $20.09.
What is the market capitalisation of ADRX?
ADRX has a market capitalisation of $2.05B on NASDAQ/NYSE.
What is the P/E ratio of ADRX?
ADRX trades at a trailing price-to-earnings (P/E) ratio of -20.71. Its price-to-book (P/B) ratio is -10.15.
What is the return on equity (ROE) of ADRX?
ADRX has a return on equity (ROE) of 36.14%. Its return on capital employed (ROCE) is -18.52%.
Is ADRX a good stock to buy?
This page provides a data-driven analysis of ADRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.